Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases [Yahoo! Finance]
Chemomab Therapeutics Ltd. - American Depositary Shares (CMMB)
Company Research
Source: Yahoo! Finance
— New CM-101 Patents Granted by Brazil and Israel Provide Additional Protections for Composition of Matter and for Use in Fibrotic Diseases of the Liver, including PSC— —Further Extend Protections Afforded by Multiple CM-101 Patents that Have Issued in the U.S., Europe Israel and Related Territories— TEL AVIV, Israel Feb. 20, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the Patent Offices in Brazil and Israel have granted new patents for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive diseases involving fibrosis and inflammation. CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC). Patient enrollment in t
Show less
Read more
Impact Snapshot
Event Time:
CMMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMMB alerts
High impacting Chemomab Therapeutics Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CMMB
News
- Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business UpdateGlobeNewswire
- Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis [Yahoo! Finance]Yahoo! Finance
- Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic SclerosisGlobeNewswire
- Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 [Yahoo! Finance]Yahoo! Finance
- Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024GlobeNewswire
CMMB
Sec Filings
- 3/28/24 - Form 20-F
- 3/11/24 - Form SC
- 3/7/24 - Form 6-K
- CMMB's page on the SEC website